MYNZ

MKT CAP:$3M

Mainz Biomed B.V.

Market Cap

$3M

Healthcare·Medical - Diagnostics & Research·🇩🇪 Germany·NASDAQ

Healthcare·Medical·🇩🇪·NASDAQ

Stock Price

$0.51-$0.65 (-56.40%)

Apr 13, 2026

Company Details

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert...

CEO

Guido Baechler

IPO Date

Nov 5, 2021

Website

mainzbiomed.com

Key Metrics TTM

Revenue

$1M

+37.7% YoY

Net Income

-$38M

EPS (Diluted)

-$30.14

Free Cash Flow

-$28M

Revenue / Share

$0.24

Gross Margin

24.4%

Operating Margin

-2249.7%

Net Margin

-2645.7%

FCF Margin

-1979.3%

P/S

1.9x

P/E

—

Earnings Reports

FY 2025

Mar 31, 2026

$537.1K-39.9%EPS -$2.70

Q4 2025

Mar 31, 2026

$250.4K-32.9%EPS -$0.05

Q2 2025

Sep 26, 2025

$286.7K-44.9%EPS -$2.65

FY 2024

Mar 31, 2025

$894.0K-0.2%EPS -$22.36

Q4 2024

Mar 31, 2025

$373.2K+73.8%EPS -$7.71

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 19	$70.3K	-$15.3K	-$187.9K
Q4 19	$70.3K	-$15.3K	-$187.9K
Q2 20	$246.8K	$61.5K	-$178.2K
Q4 20	$246.8K	$61.5K	-$178.2K
Q2 21	$417.3K	$352.5K	-$240.8K
Q4 21	$160.0K	-$174.9K	-$9M
Q4 23	$214.8K	$40.3K	-$12M
Q2 24	$520.8K	$319.0K	-$10M
Q4 24	$373.2K	$255.8K	-$9M
Q2 25	$286.7K	-$310.3K	-$8M
Q4 25	$250.4K	$84.4K	-$5M

Valuation

Quarter	P/S	P/E
Q2 19	—	—
Q4 19	—	—
Q2 20	—	—
Q4 20	6504.0x	—
Q2 21	4204.1x	—
Q4 21	5446.6x	—
Q4 23	24.7x	—
Q2 24	10.2x	—
Q4 24	3.5x	—
Q2 25	1.0x	—
Q4 25	0.8x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 19	-$104.1K	-$104.1K
Q4 19	-$104.1K	-$104.1K
Q2 20	-$234.4K	-$239.2K
Q4 20	-$234.4K	-$239.2K
Q2 21	-$228.8K	-$233.3K
Q4 21	-$3M	-$3M
Q4 23	-$5M	-$5M
Q2 24	-$8M	-$8M
Q4 24	-$9M	-$9M
Q2 25	-$7M	-$7M
Q4 25	-$4M	-$4M

Capital Expenditures

Quarter	CapEx
Q2 19	$0
Q4 19	$0
Q2 20	$4.8K
Q4 20	$4.8K
Q2 21	$4.6K
Q4 21	$12.1K
Q4 23	$261.8K
Q2 24	$120.7K
Q4 24	$134.3K
Q2 25	$1.1K
Q4 25	$93

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 21	+493.2%	+154.8%
Q4 21	+127.5%	+3629.4%
Q4 23	-13.0%	+2828.9%
Q2 24	+111.0%	+2330.5%
Q4 24	-10.6%	+1307.4%
Q2 25	+79.2%	-13.0%
Q4 25	+16.6%	-54.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 19	$0	0.0%
Q4 19	$0	0.0%
Q2 20	$0	0.0%
Q4 20	$0	0.0%
Q2 21	$2M	385.2%
Q4 21	$6M	4017.9%
Q4 23	$819.0K	381.3%
Q2 24	$1M	197.5%
Q4 24	$108.0K	29.0%
Q2 25	$1M	468.8%
Q4 25	-$141.2K	-56.4%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q2 19	$62.6K	$142.6K	$45.4K
Q4 19	$62.6K	$142.6K	$45.4K
Q2 20	$155.9K	$229.2K	$55.2K
Q4 20	$155.9K	$229.2K	$55.2K
Q2 21	$206.1K	$250.7K	$150.3K
Q4 21	$260.5K	$8M	$807.2K
Q4 23	$4M	$4M	$1M
Q2 24	$3M	$5M	$2M
Q4 24	$3M	$4M	$2M
Q2 25	$3M	$3M	$2M
Q4 25	$2M	$2M	$1M

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 19	$50.9K	$0	$50.9K
Q4 19	$203.6K	$0	$203.6K
Q2 20	$30.6K	$0	$30.6K
Q4 20	$122.6K	$0	$122.6K
Q2 21	$195.2K	$0	$195.2K
Q4 21	$9M	$0	$9M
Q2 22	$26M	$0	$26M
Q4 22	$17M	$0	$17M
Q2 23	$11M	$0	$11M
Q4 23	$7M	$0	$7M
Q2 24	$977.8K	$0	$977.8K
Q4 24	$6M	$0	$6M
Q2 25	$2M	$0	$2M
Q4 25	$889.1K	$0	$889.1K

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 19	12M	—	—
Q4 19	12M	0.0%	—
Q2 20	23M	+100.0%	—
Q4 20	23M	0.0%	—
Q2 21	12M	-48.7%	+2.6%
Q4 21	9M	-26.6%	-24.7%
Q4 23	442K	-95.0%	-98.1%
Q2 24	559K	+26.4%	-97.6%
Q4 24	968K	+73.3%	-91.9%
Q2 25	3M	+224.8%	-64.3%
Q4 25	6M	+90.7%	+1256.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 19	—	—
Q4 19	—	—
Q2 20	—	—
Q4 20	—	—
Q2 21	—	—
Q4 21	$3	52K
Q4 23	$4	53K
Q2 24	$10	53K
Q4 24	$7	53K
Q2 25	$5	53K
Q4 25	$25.0K	10

Revenue / Employee